Abstract
Background
S-1 (TS-1®) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies.
Methods
Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed.
Results
One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1–12 courses). The response rate was 37.9% (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6% (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5% (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2% and 24.3%, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia.
Conclusion
Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.
Article PDF
Similar content being viewed by others
References
T Takechi K Nakano J Uchida A Mita K Toko S Takeda et al. (1997) ArticleTitleAntitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats Cancer Chemother Pharmacol 39 205–11 Occurrence Handle8996521 Occurrence Handle1:CAS:528:DyaK2sXis1ajsL4%3D
M Fukushima Y Shimamoto T Kato J Uchida R Yonekura H Ohshimo et al. (1998) ArticleTitleAnticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous infusion of 5-fluorouracil Anticancer Drugs 9 817–23 Occurrence Handle9840729 Occurrence Handle1:CAS:528:DyaK1cXnsF2nu7c%3D
M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi et al. (1998) ArticleTitlePreclinical antitumor efficacy of S-1 2-a: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693–8 Occurrence Handle9735397 Occurrence Handle1:CAS:528:DyaK1cXmsVClurw%3D
T Shirasaka Y Shimamoto M Fukushima (1993) ArticleTitleInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004–9 Occurrence Handle7689420 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsrk%3D
Y Maehara S Nagayama H Okazaki H Nakamura T Shirasasa S Fujii (1981) ArticleTitleMetabolism of 5-fluorouracil in various human normal and tumor tissues Gann 72 824–7 Occurrence Handle6176492 Occurrence Handle1:CAS:528:DyaL38XnvFChtQ%3D%3D
MC Etienne S Cheradame JL Fischel FP Formento O Dassonville N Renee et al. (1995) ArticleTitleResponse to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J Clin Oncol 13 1663–70 Occurrence Handle7602356 Occurrence Handle1:STN:280:DyaK2MzisFyrtg%3D%3D
K Tatsumi M Fukushima T Shirasaka S Fujii (1987) ArticleTitleInhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res (Gann) 78 748–55 Occurrence Handle1:CAS:528:DyaL2sXlvFSntL8%3D
K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi et al. (1999) ArticleTitleAn early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202–10 Occurrence Handle10545788 Occurrence Handle10.1159/000012032 Occurrence Handle1:CAS:528:DyaK1MXmvF2msr0%3D
Y Sakata A Ohtsu N Hirokoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat pottassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano (2000) ArticleTitleHasegawa K, and the S-1 gastrointestinal cancer study group. Phase II study for S-1, a novel derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
BibInstitutionalEditorNameJapanese Research Society for Gastric Cancer (Eds) (1993) General rules for gastric cancer study (in Japanese) EditionNumber12th Ed. Kanehara Tokyo 109–46
BibInstitutionalEditorNameJapanese Research Society for Gastric Cancer (Eds) (1995) Japanese classification of gastric carcinoma. Part IV. Response assessment of chemotherapy for gastric carcinoma EditionNumber1st English Ed. Kanehara Tokyo 90–104
Japan Society (1993) ArticleTitlefor Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy J Jpn Soc Cancer Ther 28 101–30
J Lokich JD Ahlgren JJ Gullo JA Philips JG Fryer (1989) ArticleTitleA prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study J Clin Oncol 7 425–32 Occurrence Handle2926468 Occurrence Handle1:STN:280:DyaL1M7nslChsQ%3D%3D
RM Hansen (1991) ArticleTitle5-Fluorouracil by protracted venous infusion: a review of recent clinical studies Cancer Invest 9 637–42 Occurrence Handle1747791 Occurrence Handle1:STN:280:DyaK38%2Fotleksw%3D%3D
T Yamao Y Shimada H Kondo K Shirao T Yokota K Sugano et al. (1995) ArticleTitleClinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer Jpn J Clin Oncol 25 46–50 Occurrence Handle7745822 Occurrence Handle1:STN:280:DyaK2M3msVGksQ%3D%3D
T Moynihan R Hansen T Anderson E Quebbeman P Beatty R Ausman et al. (1988) ArticleTitleContinuous 5-fluorouracil infusion in advanced gastric carcinoma Am J Clin Oncol 11 461–4 Occurrence Handle3407626 Occurrence Handle1:STN:280:DyaL1czgslehtw%3D%3D
K Kondo M Murase Y Kodera S Akiyama K Ito Y Yokoyama et al. (1996) ArticleTitleFeasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer Oncology 53 64–7 Occurrence Handle8570135 Occurrence Handle1:CAS:528:DyaK28XhsV2mtbg%3D Occurrence Handle10.1159/000227537
YS Chung Y Yamashita T Inoue T Matsuoka B Nakata N Onoda et al. (1997) ArticleTitleContinuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma Cancer 80 1–7 Occurrence Handle9210702 Occurrence Handle10.1002/(SICI)1097-0142(19970701)80:1<1::AID-CNCR1>3.0.CO;2-# Occurrence Handle1:CAS:528:DyaK2sXksVKjtbY%3D
R Kim S Murakami Y Ohi H Inoue K Yoshida TA Toge (1999) ArticleTitlephase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer Int J Oncol 15 921–6 Occurrence Handle10536174 Occurrence Handle1:CAS:528:DyaK1MXnsFGisL8%3D
KJ Scanlon EM Newman Y Lu DG Priest (1986) ArticleTitleBiochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells Proc Natl Acad Sci USA 83 8923–5 Occurrence Handle3466165 Occurrence Handle1:CAS:528:DyaL2sXktlKjtQ%3D%3D
K Hirata N Horikoshi K Aiba M Okazaki R Dennno K Sasaki et al. (1999) ArticleTitlePharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000–5 Occurrence Handle10473078 Occurrence Handle1:STN:280:DyaK1MvgtVSmtQ%3D%3D
Y Maehara K Sugimachi M Kurihara T Taguchi (1999) ArticleTitleClinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer (in Japanese with English abstract) Jpn J Cancer Chemother 26 476–85 Occurrence Handle1:STN:280:DyaK1M7pslyitQ%3D%3D
T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ohta et al. (1998) ArticleTitleLate phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group A) (in Japanese with English abstract) Jpn J Cancer Chemother 25 1915–24 Occurrence Handle1:STN:280:DyaK1M%2FhsVGnug%3D%3D
M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ohta et al. (1999) ArticleTitleA late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group B) (in Japanese with English abstract) Jpn J Cancer Chemother 26 487–96 Occurrence Handle1:STN:280:DyaK1M7pslyiug%3D%3D
JA Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten et al. (1991) ArticleTitleSequential high-dose methotrexate and fluorouracil combined with doxorubicin — a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827–31 Occurrence Handle2016625 Occurrence Handle1:STN:280:DyaK3M3gt1ajuw%3D%3D
A Webb D Cunningham H Scarffe P Harper A Norman JK Joffe et al. (1997) ArticleTitleRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261–7 Occurrence Handle8996151 Occurrence Handle1:CAS:528:DyaK2sXnsV2msA%3D%3D
JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper et al. (1999) ArticleTitleLong-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269–72 Occurrence Handle10390007 Occurrence Handle10.1038/sj.bjc.6690350 Occurrence Handle1:CAS:528:DyaK1MXjtFyksbo%3D
D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman et al. (1992) ArticleTitleFAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541–8 Occurrence Handle1548519 Occurrence Handle1:STN:280:DyaK387ptl2lsw%3D%3D
A Ohtsu Y Shimada S Yoshida H Saito S Seki K Morise et al. (1994) ArticleTitlePhase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from Japan Clinical Oncology Group (JCOG) Eur J Cancer 30A 2091–3 Occurrence Handle7857709 Occurrence Handle1:STN:280:DyaK2M7mtFWntA%3D%3D
Ohtsu A, Boku N, Nakashima F, Koizumi W, Tanabe S, Saigenji K, et al. A phase I/II study of S-1 plus cisplatin (CDDP) in patients with advanced gastric cancer (AGC). Proceedings of ASCO 2001;20:165
Y Kano M Akutsu S Tsunoda J Ando J Matsui K Suzuki et al. (1996) ArticleTitleSchedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro Br J Cancer 74 704–10 Occurrence Handle8795571 Occurrence Handle1:CAS:528:DyaK28XmtF2mur0%3D
BT Hill RDH Whelan SA Shellard S Mcclean LK Hosking (1994) ArticleTitleDifferential tumor cell lines and certain drug resistant sublines in vitro Invest New Drugs 12 169–82 Occurrence Handle7896535 Occurrence Handle10.1007/BF00873957 Occurrence Handle1:CAS:528:DyaK2MXjsVCmtb4%3D
S Miyamoto N Boku A Ohtsu S Yoshida A Ochiai H Okabe et al. (2000) ArticleTitleClinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study group of S-1 for gastric cancer Int J Oncol 17 653–58 Occurrence Handle10995874 Occurrence Handle1:CAS:528:DC%2BD3cXntFOmur0%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, I., Kakeji, Y., Emi, Y. et al. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. Gastric Cancer 6 (Suppl 1), 28–33 (2003). https://doi.org/10.1007/s10120-003-0228-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0228-5